SCHEMBL30748374

SCHEMBL30748374

O=C1CCc2ccc(Cl)cc2C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.54
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
METAP1 P53582 1/20 0.47
PNMT P11086 1/20 0.46
AHR P35869 2/20 0.44
CMA1 P23946 1/20 0.44
SRD5A1 P18405 5/20 0.42
F7 P08709 1/20 0.42
PARP1 P09874 1/20 0.42
F3 P13726 1/20 0.42
PARP10 Q53GL7 1/20 0.42
SRD5A2 P31213 2/20 0.41
NOTUM Q6P988 3/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269917 1.00 CYP2A6 (0.54) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL588130 0.92 CYP2A6 (0.54) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL5143608 0.88 HTR2A (0.46) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL1800067 0.85 METAP1 (0.52) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL16559360 0.84 HTR2A (0.58) HTR2AHTR2CHTR2BMETAP1PNMT
SCHEMBL27844095 0.81 CYP2A6 (0.42) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL27844072 0.81 CYP2A6 (0.42) CYP2A6HTR2AHTR2CHTR2BMETAP1
Pyrrolidine SCHEMBL10564943 0.81 HTR2C (0.56) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL12430509 0.80 HTR2A (0.46) CYP2A6HTR2AHTR2CHTR2BMETAP1
SCHEMBL15962624 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573077-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2025-06-25 EP disclosed
WO-2024249252-A1 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
WO-2024040235-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed